Phase 2 study of S-IROX as down staging chemotherapy for borderline resectable pancreatic cancer

Phase 2 study of S-IROX as down staging chemotherapy for borderline resectable pancreatic cancer - BR-SIROX

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000033796

Enrollment

Registered

2018-08-20

Start date

2018-05-25

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pancreatic cancer(borderline resectable)

Interventions

chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Borderline Resectable

Exclusion criteria

Exclusion criteria: History of treatment of other cancer

Design outcomes

Primary

Measure	Time frame
R0 Resectability	—

Countries

Japan

Contacts

Public ContactYuta Maruki

National Canser Center Department of Hepatobiliary and Pancreatic Oncology

ymaruki@ncc.go.jp03-3542-2511

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026